Back grey_arrow_rt.gif
 
Latest articles about Hepatitis C.
 
null.gif
 
 
  1. EASL: Locteron Viral Kinetics and Anti-Viral Activity during Treatment with a Controlled-Release Interferon Alfa-2b in Genotype 1 Chronic Hepatitis C Patients - (05/06/08)
     
  2. EASL: POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR, R7128, IN COMBINATION WITH PEG-IFN a-2a AND RIBAVIRIN - (05/06/08)
     
  3. EASL: High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin - (05/06/08)
     
  4. EASL: RVR & Ribavirin Dose Predict SVR - (05/05/08)
     
  5. EASL: Biolex Therapeutics Researchers Present Locteron (controlled-release interferon alpha) Phase 2a Hepatitis C Trial Results at EASL Conference - (05/05/08)
     
  6. EASL: EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY - (05/05/08)
     
  7. EASL: Several Key Pegasys Studies at EASL 2008 - (05/05/08)
     
  8. EASL: Association of Pre-Treatment and On-Treatment Factors With Null Response in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin - (05/05/08)
     
  9. EASL: Sustained Virologic Response After Peginterferon alfa-2b and Ribavirin Treatment Predicts 99% Long-term Clearance of HCV at 5-Year Follow-up - (05/05/08)
     
  10. EASL: Platelet Count (and fibrosis stage) Predicts Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin (I/R) Non-Responders (NR): Results from the EPIC3 Program - (05/05/08)
     
  11. EASL: Treatment of Chronic Hepatitis C with Telaprevir (TVR) in Combination with Peginterferon Alfa-2a with or without Ribavirin: Interim Results of the PROVE2 Study - (05/02/08)
     
  12. EASL: SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT RESPONDING TO ANTIVIRAL COMBINATION THERAPY - (05/02/08)
     
  13. EASL: Results of a Safety, Tolerability and Pharmacokinetic Phase I Study of VCH-916, a Novel Polymerase Inhibitor for HCV, Following Single Ascending Doses in Healthy Volunteers - (05/02/08)
     
  14. EASL: Preclinical Pharmacokinetic and ADME Characterization of VCH-916, a Novel Non-Nuclesoside HCV NS5B Polymerase Inhibitor - (05/02/08)
     
  15. EASL: Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759, and Viral Load Declines - (05/02/08)
     
  16. EASL: Important Progress Toward Control of Hepatitis B and C - (05/01/08)
     
  17. EASL: Incidence Rates and Risk Factors Associated with Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease Due to Hepatitis C: Results of the HALTC Trial; Is the HALT-C Study Design Flawed??? - (05/01/08)
     
  18. EASL: Interim Results from HCV SPRINT-1: RVR/EVR from Phase 2 Study of Boceprevir Plus Peginterferon alfa-2b/Ribavirin in Treatment-Naive Subjects with Genotype-1 CHC - (04/30/08)
     
  19. EASL: DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1 INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL POTENCY - (04/30/08)
     
  20. EASL: New HCV Drugs Panel Discussion at EASL 2008 - (04/30/08)
     
  21. EASL: Boceprevir (NS3 Protease Inhibitor) Combination Therapy in Non Responders: Phase II Dose Finding Study - (04/30/08)
     
  22. EASL: Sustained Viral Response Is Dependent On Baseline Characteristics In The Re-treatment Of Previous Interferon/Ribavirin Non-responders: Final Results From The EPIC3 Program - (04/30/08)
     
  23. EASL: Romark Announces Presentation of New Data For Nitazoxanide in Chronic Hepatitis C at EASL 2008 - (04/29/08)
     
  24. EASL: Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C - (04/28/08)
     
  25. EASL: Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study - (04/28/08)
     
  26. EASL: Potent Antiviral Activity of 2nd Generation HCV Nucleotide Inhibitors, IDX102 and IDX184, in HCV-infected Chimps - (04/28/08)
     
  27. EASL: In Vitro Activity and Pharmacologic Properties of Two Novel Series of HCV Protease Inhibitors - (04/28/08)
     
  28. EASL: HALT-C Study Design Flawed - (04/28/08)
     
  29. EASL: Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a in treatment naive chronic HCV patients - (04/28/08)
     
  30. EASL: Peginterferon Alfa-2a (Pegasys) plus Ribavirin versus Peginterferon alfa-2b (Pegintron) Plus Ribavirin in Naive Patients with Chronic HHCV Infection: Results of a Prospective Randomized Trial - (04/28/08)
     
  31. EASL: Final Results of the Phase IIIb IDEAL Study (Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL PegInterferon Therapy) - (04/28/08)
     
  32. EASL: ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER - (04/25/08)
     
  33. EASL: Safety of the HCV Protease Inhibitor TMC435350 in Healthy Volunteers and Safety and Activity in Chronic Hepatitis C Infected Individuals: A Phase I Study - (04/25/08)
     
  34. EASL: HCV Protease Inhibitor Telaprevir, PROVE1 Study: final results of a phase 2 study with peginterferon plus ribaviron in treatment-naive patients with hepatitis C - (04/25/08)
     
  35. EASL: A Study of Telaprevir (TVR) with Peginterferon Alfa-2a (P) and Ribavirin (R) in Subjects with Well-Documented Prior PR Null Response, Non-Response or Relapse: Preliminary Results - (04/25/08)
     
  36. EASL: Study shows positive findings in treating patients with advanced hepatitis C - (04/25/08)
     
  37. EASL: COLCHICINE VERSUS PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT TRIAL - (04/25/08)
     
  38. EASL: FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION - (04/25/08)
     
  39. EASL: RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN INDEPENDEND PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF HEPATITIS C GENOTYPE 2/3 (NORDYNAMIC TRIAL) - (04/25/08)
     
  40. EASL: Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment - (04/24/08)
     
  41. Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments - (04/24/08)
     
  42. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results - (04/23/08)
     
  43. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update - (04/23/08)
     
  44. High Prevalence of Hepatitis C Virus Infection Among Immigrants From the Former Soviet Union in the New York City Metropolitan Area: Results of a Community-Based Screening Program - (04/22/08)
     
  45. Vertex Telaprevir HCV Protease Inhibitor Could Be A Winner; 2.5 million untreated/undiagnosed - (04/21/08)
     
  46. Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis - (04/21/08)
     
  47. HCV & increased risk non-Hodgkin's Lymphoma: Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium - (04/21/08)
     
  48. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study - (04/21/08)
     
  49. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 - (04/18/08)
     
  50. Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients; And New HCV Drugs in development - (04/17/08)
     
  51. ViroPharma, Wyeth stop development of hepatitus C drug HCV-796 - (04/17/08)
     
  52. How does interferon inhibit HCV cell entry? Commentaries - (04/16/08)
     
  53. Targeting siRNA to arrest fibrosis - (04/16/08)
     
  54. Fluvastatin Inhibits Hepatitis C Replication in Humans- But Not Much - (04/16/08)
     
  55. Hepatitis C : Identification Of A Protein That Inhibits The Virus - (04/15/08)
     
  56. Building a liver disease policy in the European Union - (04/04/08)
     
  57. ALT Predicts Mortality & General Health - (04/04/08)
     
  58. Positive New Info on HCV Protease Inhibitor ITMN-191 - (04/02/08)
     
  59. New HCV Protease Inhibitor Telaprevir: 80% of Treatment-Experienced Patients Achieve Early Viral Response - (04/02/08)
     
  60. Hepatitis C cases in New York expected to soar in a decade; 1 in 24 New Yorkers have hepatitis C: 340,000 in NYS - (03/31/08)
     
  61. FDA Approves Label Revisions Recommending New Robetol (ribavirin) Weight-Based Dosing Regimen: PEGINTRON PLUS WEIGHT-BASED REBETOL (ribavirin) RESULTED IN HIGHER SVR THAN FLAT DOSING; LOW RELAPSE RATES IN PATIENTS WITH CHRONIC HEPATITIS C. Schering Plough press release - (03/28/08)
     
  62. New HCV Therapy Approach - Nature Publishes Study by Santaris Pharma Scientists and Collaborators: LNA-Mediated MicroRNA Silencing in Non-Human Primates - (03/28/08)
     
  63. U.S. hepatitis C soars in those over 45 - (03/26/08)
     
  64. HCV Death Rates 50% Underestimated - (03/26/08)
     
  65. UNOS Liver Transplant Waiting List: Is it a Scandal?? - (03/24/08)
     
  66. HCV Therapy: TT-033, novel RNA interference product Oncolys and Tacere partner in hepatitis C drug development - (03/17/08)
     
  67. HIV Proteins Accelerate Liver Disease; HIV Increases HCV Replication in a TGF-ß1-Dependent Manner - (03/14/08)
     
  68. CROI: Hepatitis C Viremia following Sustained Virological Response to Pegylated Interferon and Ribavarin in HIV+ Men Who Have Sex with Men-Re-infection or Late Relapse? (03/13/08)
     
  69. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus - (03/12/08)
     
  70. Worse Survival & HCV Recurrence in Coinfected After Transplantation - (03/12/08)
     
  71. Glucose >100 mg/dl Reduces Interferon/RBV SVR - (03/10/08)
     
  72. PBMC Not A Reservoir for HCV for Patients Who Clear HCV RNA, Study Reports - (03/07/08)
     
  73. CROI: Liver histology and hepatic mitochondrial function in HIV-1-infected patients on antiretroviral therapy with chronic transaminase elevation - (03/07/08)
     
  74. Changing trends in hepatitis C-related mortality in the United States, 1995-2004 - (03/06/08)
     
  75. FDA Grants Priority Review to GSKs ITP Drug Promacta: the drug increases platelet counts; phase III studies for use in HCV are still ongoing - (03/03/08)
     
  76. Team Identifies Human Antibodies that Prevent Hepatitis C Virus Infection in Mouse Model - (02/28/08)
     
  77. HCV May Directly Cause Insulin resistance - (02/28/08)
     
  78. CROI: On-treatment responses at weeks 4 and 12 can be used to predict sustained virologic response rates in HIV HCV co-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (02/22/08)
     
  79. CROI: Week 4 or 12 Response to PegIFN Predicts Sustained Response With HCV/HIV - Written by Mark Mascolini (02/28/08)
     
  80. The way forward in HCV treatment - finding the right path: New HCV Drugs, resistance - (02/27/08)
     
  81. Nothing new in anaemia drug EPO meta-analysis, say Amgen and J&J - (02/27/08)
     
  82. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C - (02/22/08)
     
  83. Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer - (02/20/08)
     
  84. Influence of Cannabis Use on Severity of Hepatitis C Disease - (01/29/08)
     
  85. Treatment of Hepatitis C Reduces Incidence of Non-Hodgkin's Lymphoma - (01/23/08)
     
  86. Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor - (01/23/08)
     
  87. Roche responds to announcement of 'IDEAL' hepatitis C trial results - (01/14/08)
     
  88. SCHERING-PLOUGH REPORTS TOP-LINE RESULTS OF THE IDEAL STUDY First Large Study Comparing Leading Hepatitis C Therapies Shows Similar Sustained Response Rates; Fewer Patients Relapsed Following PEGINTRON Combination Therapy - (01/14/08)
     
  89. IDEAL Study COMMENTARY- Doug Dieterich MD A Healthy Dose of Curiosity Clinical trial results require careful interpretation - (01/14/08)
     
  90. Stem cell therapy for chronic liver disease-choosing the right tools for the job Commentaries - (01/14/08)
     
  91. InterMune Announces Continuing Progress on HCV Protease Inhibitor ITMN-191 (R7227) - (01/08/08)
     
  92. Pfizer/Benitec to develop Hepatitis C drug - (01/08/08)
     
  93. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3 - (01/07/08)
     
  94. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C - (01/07/08)
     
  95. Genetic Variation May Double Risk of Liver Cancer - (01/04/08)
     
  96. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial - (01/03/08)
     
  97. Genetic Variation May Double Risk of Liver Cancer - (01/02/08)
     
  98. HCV Coinfection Problem in India, Despite HAART - (12/27/07)
     
  99. HCV Coinfection Biggest Problem in India - (12/27/07)
     
  100. GSK files eltrombopag for chronic ITP (thrombocytopenia) with the FDA - (12/21/07)
     
  101. Valeant Pharmaceuticals Sells Hep-C Drug Infergen to Three Rivers Pharmaceuticals, LLC for $91 Million - (12/21/07)
     
  102. GB Virus C Reduced HCV-Liver Disease in HIV/HCV Coinfected - (12/18/07)
     
  103. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis - (12/12/07)
     
  104. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART - (12/12/07)
     
  105. Liver cancer set to soar in UK - (12/04/07)
     
  106. AASLD: Multiple dose safety and pharmacokinetic study of bavituximab in patients with chronic hepatitis C virus (HCV) infection - (11/30/07)
     
  107. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C - (11/29/07)
     
  108. Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura - (11/29/07)
     
  109. Inovio Biomedical Partner Tripep Treats First Subject in Phase I/II Study of Novel Hepatitis C DNA Vaccine - (11/28/07)
     
  110. Medivir: Initiation of a Phase IIa Clinical Trial with Investigational Hepatitis C Protease Inhibitor TMC435350 - (11/27/07)
     
  111. Report: about 38 million Chinese carry hepatitis C virus - (11/27/07)
     
  112. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response - (11/27/07)
     
  113. Inhibitex Obtains License To HCV Polymerase Inhibitors - (11/27/07)
     
  114. Roche and Maxygen terminates hepatitis drug project - (11/27/07)
     
  115. Pfizer snaps up Coley Pharmaceutical for $164 million - (11/19/07)
     
  116. New HCV Gene microRNA Therapy Research - (11/19/07)
     
  117. AASLD: Higher Caffeine Consumption is associated with Milder Fibrosis in patients with Chronic Liver Diseases - (11/16/07)
     
  118. AASLD: Hepatitis D Virus; Triply Infected HIV/HBV/HCV Progress More Quickly - (11/16/07)
     
  119. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy - (11/15/07)
     
  120. Improved cognitive function as a consequence of hepatitis C virus treatment - (11/15/07)
     
  121. AASLD: MAINTENANCE THERAPY FOUND INEFFECTIVE HALT-C STUDY - (11/14/07)
     
  122. AASLD: Rapid Virological Response at Week 4 Is the Best Predictor of Treatment Outcome in Patients With Chronic Hepatitis C: A Multivariate Analysis - (11/14/07)
     
  123. AASLD: Predictability of Response: Positive and Negative Predictive Values of Rapid and Early Virologic Responses to Peginterferon alfa-2b and Ribavirin in the Treatment of Chronic Hepatitis C - (11/14/07)
     
  124. AASLD: Final Results of the Canadian POWeR (Pegetron Prospective Optimal Weight-Based Dosing Response) Program. Sustained Virologic Response (SVR) to Weight-Based Peginterferon alfa-2b + Ribavirin in a Large, Mixed, Community and Academic Observational Study - (11/14/07)
     
  125. AASLD: Clinical Relevance of Rapid Virological Response (RVR) in Decompensated HCV-Related Cirrhosis Treated With Peginterferon and Ribavirin - (11/14/07)
     
  126. AASLD: Assessment of Virological Response at Week 4 and at Week 12 Optimizes Prediction of Treatment Outcome in Patients With Chronic Hepatitis C Treated With Peginterferon alfa-2b Plus Ribavirin - (11/14/07)
     
  127. AASLD: Patients co-infected with HCV and HIV who achieve an RVR (HCV RNA <50 IU/mL at week 4) or cEVR (HCV RNA <50 IU/mL at week 12) have similar rates of SVR to mono-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (11/13/07)
     
  128. AASLD: Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (11/13/07)
     
  129. AASLD: Response-guided therapy in a prospective trial of peginterferon alfa-2a (40KD)/ribavirin treatment in patients with HCV genotype 1 or 4 - (11/13/07)
     
  130. AASLD: What is the impact of higher sensitivity assay on response-guided therapy in hepatitis C virus (HCV)? Comparative analysis between COBAS TaqMan™ and COBAS Amplicor™ tests from two large, randomized, international trials of PEGASYS plus COPEGUS - (11/13/07)
     
  131. AASLD: Outcomes in HIV-HCV co-infected genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin 1000 or 1200 mg/day: predictions based on generalized additive models - (11/13/07)
     
  132. AASLD: Results of a Phase I Placebo-Controlled Trial in Healthy Volunteers to Examine the Safety, Tolerability and PK of the HCV Protease Inhibitor TMC435350 after Single and Repeated Dosing in healthy volunteers - (11/13/07)
     
  133. AASLD: In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor TMC435350 - (11/13/07)
     
  134. AASLD: Insulin Resistance Predicts HCV Progression in Genotype 1 - (11/13/07)
     
  135. AASLD: Pioglitazone Improved Metabolics & Liver Injury in Non-diabetics with NASH - (11/13/07)
     
  136. AASLD: Chronic hepatitis C virus infection and risk of hepatocellular carcinoma: a community-based prospective study on 19,565 residents in Taiwan - (11/13/07)
     
  137. AASLD: What is the best non invasive method for early prediction of cirrhosis in chronic hepatitis C? Prospective comparison between Fibroscan and serum markers (Lok index, APRI, AST/ALT ratio, platelet count and Fibrotest) - (11/13/07)
     
  138. AASLD: HCV patients with genotype 2 or 3 who do not achieve a rapid virologic response (RVR) with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) are not easy to treat: an analysis of non-RVR patients from the ACCELERATE study - (11/13/07)
     
  139. AASLD: High rates of sustained virologic response (SVR) in patients >50 years infected with HCV genotype 1 with positive prognostic factors treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) - (11/13/07)
     
  140. AASLD: High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 weeks with pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): prospective, randomized, controlled study comparing 24 & 48 weeks of treatment - (11/13/07)
     
  141. AASLD: The DIRECT Trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): treatment of non-responders to previous pegylated interferon plus ribavirin: sustained virologic response data - (11/9/07)
     
  142. Positive results for GlobeImmune's hepatitis C drug in Phase I - (11/09/07)
     
  143. AASLD: Tibotec HCV Protease Inhibitor - (11/9/07)
     
  144. AASLD: Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic Hepatitis C patients:Results from a randomized, double-blind, placebo -controlled, ascending multiple dose study - (11/9/07)
     
  145. AASLD: Vital Therapies Announces Presentation of ELAD "Artificial Liver" Data at American Association for the Study of Liver Diseases 2007 Annual Meeting - (11/9/07)
     
  146. AASLD: Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected patients - (11/9/07)
     
  147. AASLD: Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study - (11/8/07)
     
  148. AASLD: Rapid and early virological response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study - (11/7/07)
     
  149. AASLD: Evaluation of Viral Variants During a Phase 2 Study (PROVE2) of Telaprevir with Peg-interferon alfa-2a and Ribavirin in Treatment-naïve HCV Genotype 1-Infected Patients - (11/7/07)
     
  150. AASLD: Phase 2a study to evaluate the safety and tolerability and anti-viral of 4 doses of a novel, controlled-release interferon-alfa 2b (Locteron) given every 2 weeks for 12 weeks in treatment-naive patients with chronic hepatitis C (genotype 1) - (11/7/07)
     
  151. AASLD: Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside HCV RNA Polymerase Inhibitor, Following Multiple, Ascending, Oral Doses in Patients with HCV Genotype 1 Infection Who have Failed Prior Interferon Therapy - (11/7/07)
     
  152. GSK launches new Phase III trials of Revolade, new drug that boosts platelet counts in patients with HCV - (11/06/07)
     
  153. GlaxoSmithKline initiates trials of Promacta/Revolade (eltrombopag) for Increasing Plateket Count in HCV+ Individuals - (11/06/07)
     
  154. AASLD: Interim analysis: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C: Prove 1 - (11/7/07)
     
  155. AASLD: A high barrier to resistance may contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype 1-infected treatment-naive patients - (11/7/07)
     
  156. AASLD: Robust Synergistic Antiviral Effect of R1626 in Combination with Peginterferon alfa-2a (40KD), with or without Ribavirin, Interim Analysis Results of Phase 2a Study - (11/7/07)
     
  157. AASLD: Rapid and early virological response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study - (11/7/07)
     
  158. AASLD: Danazol Increases Platelet Counts in Thrombocytopenia Patients with Chronic Hepatitis C or Cirrhosis - (11/7/07)
     
  159. AASLD: Hepatitis C Associated Systemic Cryoglobulinemia: Successful Treatment With Plasma Exchange - (11/7/07)
     
  160. AASLD: Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction in Fibrosis and Inflammatory Scores in Chronic Hepatitis C Nonresponder Patients With Fibrosis or Cirrhosis - (11/7/07)
     
  161. AASLD: Gilead hepatitis C drug may have heart issue-study - (11/5/07)
     
  162. AASLD: Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C - (11/5/07)
     
  163. AASLD: PROVE2: phase II study of telapravir (VX-950) in combination with peginterferon alfa-2 with or without ribavirin in subjects with chronic hepatitis C, an interim analysis - (11/5/07)
     
  164. EACS: Insulin Resistance Imperils Response to Interferon in People With HCV/HIV - (11/04/06)
     
  165. AASLD: Roche's Oral Polymerase Inhibitor Shows Robust Antiviral Efficacy in Treatment of Chronic Hepatitis C - (11/2/07)
     
  166. AASLD: Pegasys High Dose Induction for PegIntron Nonresponders: REPEAT Study - (11/2/07)
     
  167. AASLD: GILEAD ANNOUNCES 48-WEEK DATA FROM TWO PIVOTAL PHASE III STUDIES EVALUATING VIREAD FOR THE TREATMENT OF CHRONIC HEPATITIS B - (11/2/07)
     
  168. AASLD: 91% OF BARACLUDE (ENTECAVIR) TREATED PATIENTS IN A FOUR-YEAR COHORT DEMONSTRATED VIROLOGIC SUPPRESSION TO UNDETECTABLE LEVELS - (11/2/07)
     
  169. AASLD: Roche Polymerase Inhibitor Shows Promise In Phase II - (11/2/07)
     
  170. Potent Abbott Hepatitis C Virus Protease Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies - (11/02/07)
     
  171. AASLD: First Studies Demonstrating Greater than 60% Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients (Vertex press release) - (11/2/07)
     
  172. AASLD: Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C - (11/2/07)
     
  173. AASLD: Vertex feeling growing pains Firm scrambles for workers, space as drug shows promise - (11/2/07)
     
  174. AASLD: Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C - (11/2/07)
     
  175. AASLD: 2 New HCV Drugs at AASLD - (11/2/07)
     
  176. New Hepatitis C Antiviral CB5300 Identified by Canopus BioPharma Researchers to Enter Clinical Trial Assessment - (11/01/07)
     
  177. Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial - (11/01/07)
     
  178. New Drug CF-102 for Liver Cancer Enters Phase 1 Clinical Trials - (10/31/07)
     
  179. Bayer and Onyx get liver cancer approval for Nexavar in EU - (10/31/07)
     
  180. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody - (10/30/07)
     
  181. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection - (10/24/07)
     
  182. INITIAL RESULTS OF PHASE II STUDY WITH HCV PROTEASE INHIBITOR BOCEPREVIR IN TREATMENT-NAIVE HEPATITIS C PATIENTS SHOW A HIGH RATE OF EARLY VIROLOGIC RESPONSE - (10/19/07)
     
  183. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus - (10/17/07)
     
  184. Marianne Faithfull Has Hepatitis C - (10/16/07)
     
  185. Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C - (10/16/07)
     
  186. Low-Dose Interferon Lozenges HCV & HIV/oral warts Study - (10/10/07)
     
  187. Discovery of a novel class of Hepatitis C Polymerase Inhibitors - (10/10/07)
     
  188. The Antiviral Efficacy of the Nonnucleoside HCV Polymerase Inhibitor A-848837 in the HCV Infected Chimpanzee - (10/05/07)
     
  189. Ultrasound-Based Transient Elastography for the Detection of Hepatic Fibrosis: Systematic Review and Meta-analysis - (10/05/07)
     
  190. Stiffness and Impedance: The New Liver Biomarkers Editorial - (10/05/07)
     
  191. Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index - (10/05/07)
     
  192. Assessment of Hepatic Fibrosis With Magnetic Resonance Elastography - (10/05/07)
     
  193. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C - (10/03/07)
     
  194. "True" weight-based dosing versus "flat' dosing of ribavirin: Will the WIN-R please come forward? Editorial - (10/03/07)
     
  195. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial - (10/03/07)
     
  196. Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype - (10/03/07)
     
  197. Intermune HCV Protease Trials Timeline - (10/01/07)
     
  198. VX950+Peg Data Without RBV at AASLD Nov - (10/01/07)
     
  199. Pharmasset HCV & HBV Drugs - (09/27/07)
     
  200. Maxygen Announces Hold on MAXY-alpha Development Program - (09/24/07)
     
  201. Preclinical Characterization of TMC435350, a novel macrocyclic inhibitor of the HCV NS3/4A serine protease - (09/24/07)
     
  202. European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy - (09/24/07)
     
  203. Helicase Target for HCV Therapy - (09/18/07)
     
  204. Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C - (09/18/07)
     
  205. XTL Biopharmaceuticals Presents a New Class of Highly Potent Small Molecule Inhibitors of Hepatitis C Affecting the NS5A Target at an International Scientific Conference - (09/18/07)
     
  206. New Treatment for Liver Cancer 'Burns Tumors Off' N&N makes cancer breakthrough - (09/13/07)
     
  207. The Use of Transient Elastometry for Assessing Liver Fibrosis in Patients with HIV and Hepatitis C Virus Coinfection: only detects cirrhosis - (09/13/07)
     
  208. New therapies for hepatitis C: VX-950 (telaprevir) - (09/11/07)
     
  209. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C - (09/11/07)
     
  210. Possible Hepatitis C vaccine - (09/05/07)
     
  211. Human Genome Sciences gets 40 mln usd Albuferon milestone payment from Novartis - (08/28/07)
     
  212. HCV Care by Liver Specialists or Community-Based Practices: Pro & Con - (08/27/07)
     
  213. Hep C vaccine shows promise - (08/21/07)
     
  214. Intercell's therapeutic Hepatitis C vaccine meets primary endpoints in Phase II interim analysis - (08/21/07)
     
  215. Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis - (08/20/07)
     
  216. Risk factors (AZT) for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin - (08/17/07)
     
  217. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (08/17/07)
     
  218. Twelve-Week Treatment of Acute Hepatitis C Virus with Pegylated Interferon-a-2b in Injection Drug Users is Effective - (08/17/07)
     
  219. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients - (08/16/07)
     
  220. Coffee drinking and hepatocellular carcinoma risk: A meta-analysis - (08/16/07)
     
  221. Inovio Biomedical Partner Tripep Receives Approval to Initiate Phase I/II Study of Novel Vaccine for Hepatitis C Virus - (08/16/07)
     
  222. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? - (08/16/07)
     
  223. Nitazoxanide+Pegasys/RBV Study for HCV - (08/15/07)
     
  224. IAS: Hepatitis C Viral Kinetics During Treatment With Weekly Versus Twice Weekly Peg IFN-alpha-2a in HIV/HCV Co-infected Patients - (08/10/06)
     
  225. Peregrine's Bavituximab HCV Phase Ib Study Results Selected for Oral Presentation at Upcoming AASLD Annual Meeting - (08/09/07)
     
  226. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy: Virahep-C Study - (08/06/07)
     
  227. Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis. Coffee, 2 Cups Daily, May Reduce Risk for Liver Disease, ALT Elevations - (08/06/07)
     
  228. Hepatitis C strongly linked to type 2 diabetes - (08/02/07)
     
  229. InterMune Submits CTA Amendment for HCV Protease Inhibitor ITMN-191 and Provides Update on Clinical Development Program - (08/02/07)
     
  230. VX-950 HCV Protease inhibitor at AASLD - (08/02/07)
     
  231. Development Discontinued for ANA975, an Early Stage Compound for Treatment of Hepatitis C Virus Infection - (08/02/07)
     
  232. Hepatitis C helicase unwinds DNA in a spring-loaded, 3-step process - (08/02/07)
     
  233. Roche/Pharmasset HCV Polymerase Drug New Patient Study Results Expected in September - (08/02/07)
     
  234. OraSure Technologies Announces Pre-Clinical Study Results for Prototype Rapid HCV Antibody Test at AACC Annual Meeting - (07/20/07)
     
  235. Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication - (07/17/07)
     
  236. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha - (07/16/07)
     
  237. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis - (07/16/07)
     
  238. Novartis, Idenix Suspend Tests on Hepatitis C Drug NM283 - (07/16/07)
     
  239. Atorvastatin (Lipitor) lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase - (07/16/07)
     
  240. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference - (07/16/07)
     
  241. Predictors of response to Pegasys/RBV of U.S. veterans to treatment for the hepatitis C virus - (07/13/07)
     
  242. Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 - Is Less More? EDITORIAL - (07/12/07)
     
  243. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3 (NEJM) - (07/12/07)
     
  244. Do high lipids help clearance of hepatitis C? - (07/12/07)
     
  245. Pharmasset and Roche Initiate Studies to Advance R7128 Polymerase Inhibitor for HCV - (07/12/07)
     
  246. HCV/HIV Coinfection in Asia - (07/05/07)
     
  247. HCV Replication Found in CNS in HIV+ - (07/03/07)
     
  248. Schering Plough Ends Celgosivir Deal - (06/28/07)
     
  249. Pakistan to launch survey on hepatitis B & C Prevalence - (06/27/07)
     
  250. New RNAi HCV Drug - (06/22/07)
     
  251. Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-κB Signaling, and HCV Infection by Standardized Silymarin (Milk thistle) - (06/20/07)
     
  252. 67% Steatosis in HCV/HIV Coinfected: : Liver inflammation, HCV genotype 3, and BMI are associated with steatosis, a common finding in HCV-HIV-coinfected patients. - (06/20/07)
     
  253. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial: no ribavirin-Valopicitabine drug interaction - (06/13/07)
     
  254. ViroPharma Announces Completion of Enrollment in 500mg BID Arms of HCV-796 Phase 2 Study - (06/13/07)
     
  255. Roche's Hepatitis C drug Pegasys patent challenged - (06/13/07)
     
  256. Phase III data looks promising for GSK's eltrombopag - (06/11/07)
     
  257. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon - (06/08/07)
     
  258. XTL-2125 Hep C Drug Fails - (06/07/07)
     
  259. Medical Resource Utilization in Chronic Liver Disease Patients with Thrombocytopenia - (06/06/07)
     
  260. DDW: Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection - (06/05/07)
     
  261. New HCV Therapy PYN17 - (06/04/07)
     
  262. Cytheris to start two phase I/IIa clinical trials of CYT107, its new recombinant Interleukin-7, in Hepatitis C and oncology - (06/04/07)
     
  263. 5% in Pakistan have HCV, 7-8 Million People - (06/04/07)
     
  264. Free IFN/RBV in Pakistan - (06/04/07)
     
  265. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients - (06/04/07)
     
  266. HCV Increased NHL Risk & Appears to Drive Immunological Stimulus for Progression to Hematological Malignancy; Interferon Can Regress NHL - (06/04/07)
     
  267. DDW: 12 weeks VX-950 Therapy - (06/04/07)
     
  268. HCV Increased NHL Risk & Appears to Drive Immunological Stimulus for Progression to Hematological Malignancy; Interferon Can Regress NHL - (05/31/07)
     
  269. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study - (05/31/07)
     
  270. Acute HCV in MSM in London - (05/31/07)
     
  271. UK and Wales Fail on HCV Policy - (05/31/07)
     
  272. Controlled Release Interferon - (05/31/07)
     
  273. Reversibility of hepatic fibrosis and cirrhosis-is it all hype? Editorial - (05/31/07)
     
  274. Hepatitis D virus infection - Not a vanishing disease in Europe! - (05/31/07)
     
  275. DDW: NY Montefiore Hospital Coinfection Program Reports Success With a Multi-Disciplinary Program: Model of Care - (05/31/07)
     
  276. CROI: HOMA-IR Is a Strong Predictor of Rapid Virologic Response in HIV/HCV-co-infected Patients Treated with Pegylated Interferon-alpha 2a and Ribavirin (05/29/07)
     
  277. CROI: Glucose Intolerance Associated with Advancing Liver Disease (Fibrosis) (05/29/07)
     
  278. CROI: Non-Invasive Liver Tests Studies Disappoint at CROI in Coinfection Studies (05/29/07)
     
  279. DDW: Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD): does fatty liver cause lipodystrophy? - (05/25/07)
     
  280. DDW: Diabetes Therapy Improves Peg/RBV Response - (05/25/07)
     
  281. DDW: Early Pegasys/RBV Therapy is Cost Effective, Improves Survival & Reduces Risk for Cirrhosis - (05/25/07)
     
  282. DDW: Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration - (05/25/07)
     
  283. DDW: Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD) - (05/24/07)
     
  284. DDW: Cost-effectiveness, Survival, and Prevention of Cirrhosis with Early Treatment of Chronic Hepatitis C with Peginterferon Alfa-2a (40KD) plus Ribavirin before Progression to Advanced Liver Disease - (05/24/07)
     
  285. DDW: HCV Can Be Cured - (05/24/07)
     
  286. DDW: Treatment Duration and Histological Response to Peginterferon Alfa-2a/Ribavirin: 48 weeks improves liver disease in Non-SVRs better than 24 weeks - (05/24/07)
     
  287. DDW: Safety and Tolerability of Peginterferon Alfa-2a Plus Ribavirin in HCV Patients Nontolerant or Nonresponsive to Peginterferon Alfa-2b Plus Ribavirin - (05/23/07)
     
  288. DDW: Celgosivir with Peginterferon and Ribavirin in Chronic Hepatitis C - (05/23/07)
     
  289. DDW: Pharmacodynamic Analysis of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Combination With Pegylated Interferon Alfa-2b in Treatment-Naive Patients With Chronic HCV - (05/23/07)
     
  290. EASL: Safety, Pharmacokinetics and Antiviral effects of Boehringer Ingelheim BILB 1941, a Novel HCV RNA Polymerase, After 5 days Oral treatment in Patients with Chronic Hepatitis C - (05/21/07)
     
  291. EASL: Phase II Proof of Concept Study of celgosivir in combination woth peginterferon alfa-2a and ribavirin in chronic hepatitis C genotype-1 non responder patients - (05/21/07)
     
  292. DDW: HCV-Infected Liver Donors for Liver Transplantation Are Recommended Instead of Uninfected HCV-Donated Livers, from a new study presented at DDW 2007 - (05/22/07)
     
  293. DDW: HCV-796, Polymerase Inhibitor - (05/22/07)
     
  294. DDW: Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection - (05/22/07)
     
  295. DDW: Increased SVR rate with 48 weeks' treatment and higher RBV dose in HCV genotype 2/3 patients without a rapid virologic response (RVR) treated with peginterferon alfa-2a (40KD) (PEGASYS) plus RBV (COPEGUS) - (05/22/07)
     
  296. DDW: Peginterferon Alfa-2a (40KD) Plus Ribavirin for 16 or 24 Wks in Pts With HCV Genotype 2/3 Infection and Advanced Fibrosis/Cirrhosis - (05/22/07)
     
  297. DDW: Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''; Mitch Shiffman says 'you can cure HCV', Eugene Schiff says 'get treated'. - (05/22/07)
     
  298. DDW: 16 vs 24 wks Pegasys/RBV in Cirrhotics & Non-Cirrhotics Genotype 2/3 from ACCELERATE Study - (05/22/07)
     
  299. DDW: Increased SVR Rate with 48 Wks' Treatment and Higher RBV Dose in HCV Genotype 2/3 Pts Without a Rapid Virologic Response (RVR) Treated with Peginterferon Alfa-2a (40KD) (PEGASYS) Plus RBV (COPEGUS) - (05/21/07)
     
  300. DDW: Statin Improved PegIFN/RBV SVR Rate, Improve ALTs in HCV+ - (05/21/07)
     
  301. DDW: InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting - (05/21/07)
     
  302. Hepatitis D virus infection - Not a vanishing disease in Europe! - (05/03/07)
     
  303. HCV Reinfection: is there protective effect following natural HCV clearance? - (05/03/07)
     
  304. EASL: Pegasys vs Peg/ADV for Hepatitis D Virus: Pegasys most effective - (05/03/07)
     
  305. EASL: HCV Antiviral Activity and Resistance Analysis in Chronically Infected Chimpanzees Treated with Merck NS3/4A Protease and NS5B Polymerase Inhibitors - (05/02/07)
     
  306. EASL: Low-Dose PegIFN Maintenance Therapy Successful - (05/02/07)
     
  307. European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV - (05/01/07)
     
  308. More gay men getting hepatitis C; Increased HCV Infection Among HIV+ Gay Men - (05/01/07)
     
  309. EASL: Albuferon Once Every 2 or 4 Weeks Interferon Looks Good in Phase 2 Study - (05/01/07)
     
  310. EASL: Inherited Variants of Genes Involved in Insulin Signaling and Lipogenesis Influence The Risk of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease - (05/01/07)
     
  311. EASL: Insulin Resistance in HBV, HCV & Non-Virus Related Chronic Hepatitis (liver enzymes) - (05/01/07)
     
  312. EASL: Insulin Resistance Inflames The Liver in HCV - (05/01/07)
     
  313. EASL: Insulin Resistance in 424 HCV+ Patients: association with HCV replication and advanced fibrosis - (05/01/07)
     
  314. EASL: Statins May Improve Liver Fibrosis - (05/01/07)
     
  315. EASL: PegIntron + 2 HCV Nucleosides Show Synergy - (04/27/07)
     
  316. New Genetic Diagnostic Tests-Financial Impact - (04/27/07)
     
  317. EASL: R1479 (R1626), a Novel Hepatitis C Polymerase Inhibitor: Lack of Pre-Existing Resistance Mutations Supports the Observed In Vivo High Barrier to Resistance - (04/27/07)
     
  318. EASL: ITMN-191 CONCENTRATIONS ACHIEVED IN THE LIVER OF ANIMALS PROMOTE HCV REPLICON CLEARANCE IN VITRO AND THIS EFFECT IS ENHANCED BY PEG-IFN a-2a (Pegasys) - (04/27/07)
     
  319. EASL: HCV Protease Inhibitor ITMN-191 Resistance - (04/27/07)
     
  320. HCV Protease Inhibitor ITMN-191 + HCV Polymerase Inhibitor R1626 Synergy - (04/27/07)
     
  321. EASL: Lipid steatosis, metabolic variables and body composition in the setting of HIV/HCV coinfection; findings from a large randomised trial (APRICOT) - (04/26/07)
     
  322. EASL: 400,000 IU/mL Is New Cut-Off for Low vs High Viral Load in HCV - (04/26/07)
     
  323. EASL: Favorable Cross-Resistance Profile of Two Novel Hepatitis C Virus Inhibitors, SCH 503034 (Boceprevir) and HCV-796, and Enhanced Anti-Replicon Activity Mediated by the Combined Use of Both Compounds - (04/26/07)
     
  324. EASL: SCH503034 & NM283 Not Cross-Resistant - (04/26/07)
     
  325. EASL: An open label, comparative, multi-center study of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B dual infection versus with mono-infected chronic hepatitis C: An interim report - (04/25/07)
     
  326. EASL: Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin - (04/25/07)
     
  327. EASL: 14 Weeks vs 24 Weeks Peg/RBV for Genotypes 2/3 - (04/20/07)
     
  328. EASL: In vitro Resistance Selection to the HCV Nucleoside Polymerase Inhibitor R1479 (R1626) and to the Protease Inhibitor VX-950 - (04/23/07)
     
  329. EASL: SVR Durable (99%) After 5 Years of Followup - (04/23/07)
     
  330. EASL: 48 Weeks & High Ribavirin Dose May Improve SVR Rates for Genotype 2/3, French study by Bernard Willems - (04/23/07)
     
  331. EASL: In Patients Who Clear HCV RNA At Week 12 (between week 8 and 12): SVR is Higher After 72 Weeks Than After 48 Weeks Treatment: Results of a Randomized Controlled Trial - (04/23/07)
     
  332. EASL: New HCV Drug Target NS4A Antagonists - (04/23/07)
     
  333. EASL: 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS - (04/20/07)
     
  334. EASL: Abbott HCV Polymerase Inhibitor - (04/18/07)
     
  335. EASL: CANNABIS USE AS AN INDEPENDENT PREDICTOR OF SEVERE STEATOSIS DURING CHRONIC HEPATITIS C - (04/19/07)
     
  336. EASL:3-Drug HCV therapy for 12 weeks: VX950+pegIFN+RBV, interim results from phase II PROVE 1 Trial - (04/17/07)
     
  337. EASL: HCV-796 Polymerase Inhibitor Shows 1.5 log Viral Load Reduction - (04/17/07)
     
  338. EASL: GSK625433: A Novel and Highly potent Inhibitor of the HCV NS5B Polymerase - (04/17/07)
     
  339. EASL: Merck HCV Protease & Polymerase Inhibitor Viral Load Reduction & Resistance in Chimps - (04/17/07)
     
  340. EASL: GSK625433: A Novel and Highly Potent Inhibitor of the HCV NS5B Polymerase - (04/17/07)
     
  341. EASL: Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C - (04/17/07)
     
  342. EASL: New HCV Drug Target NS4A Antagonists - (04/17/07)
     
  343. EASL: NM283 in Treatment-Naives Looks Better - (04/13/07)
     
  344. EASL: NM283, HCV Polymerase Inhibitor in Non-Responders - (04/13/07)
     
  345. Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines - (04/12/07)
     
  346. EASL: Resistance to New HCV Antivirals - (04/12/07)
     
  347. EASL: Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) - (04/12/07)
     
  348. EASL: New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders - (04/12/07)
     
  349. New Once Weekly Oral Interferon Belerofon in Phase 1 - (04/09/07)
     
  350. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/09/07)
     
  351. 33% HCV/HIV Coinfected in Milan, Italy - (04/09/07)
     
  352. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/05/07)
     
  353. Liver Iron Levels NOT Directly Linked to Fibrosis - (04/03/07)
     
  354. UK Parliament adopts written declaration on Hepatitis C - (03/29/07)
     
  355. Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3 - (03/27/07)
     
  356. Improved Outcomes After SVR, Interferon Therapy - (03/27/07)
     
  357. CROI: In NYC: Liver Fibrosis During Acute HCV Infection of HIV-infected Men (03/21/07)
     
  358. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection - (03/21/07)
     
  359. U.S. sees sharp decline in hepatitis cases: CDC - (03/21/07)
     
  360. Hepatitis C in Prison & After Release: 40% infected - (03/21/07)
     
  361. Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis C Patients With New PEGASYS (R) (peginterferon alfa-2a (40KD)) and COPEGUS(R) (ribavirin) Trial - (03/16/07)
     
  362. Procrit/Epogen FDA Safety Warning - (03/12/07)
     
  363. PEGASYS(R) Gets European Approval for a Shorter Treatment Duration for Some Genotype 1 and 4 Hepatitis C Patients who Show a Rapid Response to Therapy - (03/06/07)
     
  364. Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3 - (02/29/07)
     
  365. New HCV Drug R7128 Polymerase Inhibitor - (02/29/07)
     
  366. SVR Improved Quality of Life & Sexual Function in Patients with Advanced Fibrosis in HALT-C Study - (02/20/07)
     
  367. Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C Study) - (02/16/07)
     
  368. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients - (02/15/07)
     
  369. Non-invasive markers of liver fibrosis: How to use them in clinical practice? - (02/15/07)
     
  370. Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C (HALT-C Study) - (02/12/07)
     
  371. Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07)
     
  372. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/12/07)
     
  373. Short-duration therapy for hepatitis C & RVR: suitable for all? - (02/12/07)
     
  374. Liver Stiffness Measurement Versus Clinicians' Prediction or Both for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C - (02/09/07)
     
  375. Are Noninvasive Liver Fibrosis Tests Ready for Use? There are lots of questions. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C - (02/09/07)
     
  376. Medivir: Clinical Phase I Trial with Hepatitis C Virus Protease Inhibitor Initiated - (02/09/07)
     
  377. Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development - (02/09/07)
     
  378. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/01/07)
     
  379. Combination Therapy With Telaprevir and Pegylated Interferon Suppresses Both Wild-Type and Resistant Hepatitis C Virus - (02/01/07)
     
  380. Time-Released Interferon Drug: OctoPlus initiates Locteron Phase II clinical study in chronic hepatitis C - (01/30/07)
     
  381. Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07)
     
  382. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study - (01/26/07)
     
  383. New Hepatitis C Culture System for Study of Virus - (01/24/07)
     
  384. Coley Suspends Development of HCV Toll-Receptor Drug - (01/23/07)
     
  385. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia - (01/22/07)
     
  386. Diabetes, HCV and Liver Transplanation - (01/22/07)
     
  387. Arrow Therapeutics Selects a 2nd Hepatitis C Clinical Candidate - (01/22/07)
     
  388. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis - (01/22/07)
     
  389. Noninvasive Markers of Liver Fibrosis - (01/19/07)
     
  390. Negative-Strand Hepatitis C Virus (HCV) RNA in Peripheral Blood Mononuclear Cells from Anti-HCV-Positive/HIV-Infected Women - (01/11/07)
     
  391. Detection of Hepatitis C Virus (HCV) in Serum and Peripheral-Blood Mononuclear Cells from HCV-Monoinfected and HIV/HCV- Coinfected Persons - (01/11/07)
     
  392. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C - (01/09/07)
     
  393. Schering and Orasure in pact to develop oral hepatitis C test - (01/09/07)
     
  394. Successful IFN Therapy in IVDUs on Naltraxone - (01/09/07)
     
  395. Enhancing hepatitis C treatment uptake and outcomes for injection drug users EDITORIAL - (01/09/07)
     
  396. Diet (Food groups) and risk of hepatocellular carcinoma: A multicenter case-control study in Italy - (01/09/07)
     
  397. Phynova Obtains FDA Approval of its IND to Enter Into a Clinical Trial of PYN17 for the Treatment of Chronic Hepatitis C - (01/09/07)
     
  398. VX-950 Phase 2b PROVE 1 Study Interim Safety & Antiviral Activity at Week 12 - (12/20/06)
     
  399. New HCV Drug Celgosivir/MX-3253, oral alpha-glucosidase I inhibitor - (12/20/06)
     
  400. Vertex Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950) - (12/20/06)
     
  401. Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C - (12/20/06)
     
  402. Pevion Biotech Announces Its Hepatitis C Therapeutic Vaccine Enters Clinical Phase I - (12/20/06)
     
  403. InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche - (12/20/06)
     
  404. InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche - (12/20/06)
     
  405. Procrit/EP- Safety Alert from FDA - (12/18/06)
     
  406. Epoetin Alfa and Risk for Complications - (12/18/06)
     
  407. Correction of Anemia - Payoffs and Problems EDITORIAL - (12/18/06)
     
  408. ICAAC: The PRESCO study: role of extended therapy and/or optimal doses of ribavirin in the treatment of chronic hepatitis C in HIV-infected patients (12/12/06)
     
  409. Fatty Liver Associated with Increased Mortality - (12/12/06)
     
  410. Pegasys/RBV Reverses Fibrosis in HCV/HIV-Coinfected in APRICOT Study for Viral Responders, Non-responders, and Cirrhosis - (12/12/06)
     
  411. HCV Reduces Cholesterol in Coinfected; Interferon therapy Increases Cholesterol - (12/12/06)
     
  412. Diabetes and hepatocellular carcinoma Editorial - (12/12/06)
     
  413. Abbott Acquires HCV Protease Inhibitors from Enanta Pharma - (12/12/06)
     
  414. Valeant Pharmaceuticals Initiates Infergen Phase 4 Study - (12/12/06)
     
  415. Hepatitis C Virus Replicates in the Liver of Patients Who Have a Sustained Response to Antiviral Treatment - (12/06/06)
     
  416. Hepatitis C Virus Seropositivity in Organ Donors Reduced Survival in Heart Transplant Recipients - (12/06/06)
     
  417. Poorer Outcomes for Recipients of Heart Allografts From HCV-Positive Donors EDITORIAL - (12/06/06)
     
  418. HCV Infections From a Contaminated Radiopharmaceutical Used in Myocardial Perfusion Studies - (12/06/06)
     
  419. ViroPharma and Wyeth Initiate Dosing in Phase 2 Study of HCV-796 in Treatment Naive Patients and Non-Responders - (12/06/06)
     
  420. Christopher Kennedy Lawford Urges America to Face Its Silent Epidemic - Hepatitis C - (12/06/06)
     
  421. Pharmasset Initiates Phase 1 Study of R7128 for HCV - (12/06/06)
     
  422. Patients who recover from hepatitis C have lower risk of reinfection - (12/06/06)
     
  423. Racing to The Market with New HCV Drugs Vertex May Beat Roche, Merck on Drug for Hepatitis C - (12/06/06)
     
  424. HCV Drug R7128 Makes Progress - (12/06/06)
     
  425. Arrow Therapeutics HCV Compound Enters Phase I - (12/04/06)
     
  426. Saliva-based hepatitis C test developed - (12/04/06)
     
  427. New Hepatitis C Drugs - (12/04/06)
     
  428. Inovio Biomedical Partner Tripep Files Application for Phase I Clinical Study of Hepatitis C DNA Vaccine - (12/04/06)
     
  429. China's Hepatitis C Prevalent Population is Ten Times that of the United States - (12/04/06)
     
  430. AASLD: In Vitro Synergistic Antiviral Activity of ITMN-191, an Orally Active Inhibitor of the Hepatitis C Virus (HCV) NS3/4A Protease, in Combination with PEG-Interferon Alfa-2a - (11/14/06)
     
  431. AASLD: Development of HCC in Patients who Achieve SVR to IFN-Based Therapies is Associated with Cirrhosis and Prior HBV Exposure - (11/14/06)
     
  432. AASLD: CPG10101 HCV Toll-Receptor 9 Antagonist Phase II Study results - (11/10/06)
     
  433. AASLD: New HBV Drug PMEO-DAPym Active In Vitro Against Drug Resistant Mutants of HBV - (11/10/06)
     
  434. AASLD: In Vitro Resistance Studies of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-dependent RNA Polymerase - (11/08/06)
     
  435. AASLD: Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day - (11/08/06)
     
  436. AASLD: PegIntron/RBV Effective for >65 Year Olds - (11/08/06)
     
  437. AASLD: New Therapy Significantly Increases Platelet Count - (11/08/06)
     
  438. AASLD: Eltrombopag, an Oral Platelet Growth Factor, Facilitates Initiation of Interferon Therapy in Subjects with HCV Associated Thrombocytopenia - (11/08/06)
     
  439. AASLD: Merck HCV Polymerase Inhibitor - (11/08/06)
     
  440. AASLD: In Vitro Resistance Studies of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-dependent RNA Polymerase - (11/08/06)
     
  441. AASLD: Pegasys 270 ug/wk+RBV 1200/1600mg in Difficult To Treat Patients - (11/07/06)
     
  442. AASLD: Pegasys Every 5 Days in PegIntron Nonresponders - (11/07/06)
     
  443. AASLD: Hispanic Responses to PegIntron/RBV in WIN-R Study - (11/07/06)
     
  444. AASLD: LATINO Pegasys Study: early responses - (11/07/06)
     
  445. AASLD: Adefovir 3 & 5 Years Followup HBeAg+: safety & efficacy - (11/06/06)
     
  446. AASLD: 16 vs 24 weeks Pegasys/RBV for Genotype 2 HCV; Taiwan Study: Week 4 Response & Ribavirin Level/Dose Predicts SVR - (11/06/06)
     
  447. AASLD: <400,000 is New HCV RNA Cutoff In genotype 1 with Pegasys/RBV - (11/06/06)
     
  448. AASLD: 72 Weeks Pegasys/RBV in Genotype 1 Improves SVR Rate For Patients With Early Viral Response (2 log reduction at wk 12) But HCV RNA >50 IU/mL - (11/06/06)
     
  449. AASLD: 72 Weeks Peg/RBV for 'Slow-Responders' Improves SVR Rate - (11/06/06)
     
  450. AASLD: 400,000 IU/ml was the best cut-off level between Low VL and High VL - (11/06/06)
     
  451. AASLD: The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naive HIV/HCV co-infected subjects - (11/03/06)
     
  452. AASLD: Entecavir vs Adefovir in HBeAg+ Naives 24 Weeks EARLY Study - (11/03/06)
     
  453. AASLD: Ribavirin Dose/Levels Predicts Outcome in Pegasys/RBV ACCELERATE Study Comparing 16 vs 24 Weeks Therapy - (11/03/06)
     
  454. AASLD: Week 4 Response Predicts SVR in Pegasys/RBV 16 Week Therapy Study in Genotypes 2/3 - (11/03/06)
     
  455. AASLD: Win-R Study: Ribavirin Weight-Base Dosing in High Weight Patients; Treatment Responses to PegIntron/RBV for Elderly Patients and by Patient Ethnicity - (11/02/06)
     
  456. AASLD: Weight-Based Ribavirin Improves SVR Rate for Patients >125 kg (275 lbs) - (11/02/06)
     
  457. AASLD: Infergen (Consensus Interferon) Phase III DIRECT Study End of Treatment Results - (11/02/06)
     
  458. AASLD: Current status of Subjects Receiving Pegays and Ribavirin Follow-On Therapy After 28 Days Treatment with the Hepatitis C Protease Inhibitor Telaprevir (VX-950), Pegasys & RBV - (11/02/06)
     
  459. AASLD: Win-R Study: Ribavirin Weight-Base Dosing in High Weight Patients; Treatment Responses to PegIntron/RBV for Elderly Patients and by Patient Ethnicity - (11/02/06)
     
  460. AASLD: VX-950 HCV Protease Inhibitor Resistance Profile: combination therapy suppresses drug resistance - (11/01/06)
     
  461. AASLD: New Drug Lowers AST/ALT Levels in Chronic HCV - (11/01/06)
     
  462. AASLD: Albuferon Phase 2 Study Results Reported in Posters at AASLD - (11/01/06)
     
  463. AASLD: Albuferon Quality-Of-Life Reported - (11/01/06)
     
  464. 75% of College Students Report Risk Factors for Hepatitis C - (10/31/06)
     
  465. Colchicine May Delay Progression of Viral Cirrhosis to Liver Cancer - (10/31/06)
     
  466. Culturing Hepatitis C for new drugs - (10/31/06)
     
  467. HCV Alters Neurotransmission - (10/31/06)
     
  468. HCV & Neurologic Dysfunction - (10/31/06)
     
  469. Intermune/Roche HCV Protease Joins HCV Protease Battle - (10/31/06)
     
  470. Intermune Inks HCV Drug Development Agreement With Roche - (10/31/06)
     
  471. Tacere Therapeutics Secures Financing And Resumes Development Of RNAi Hepatitis C Drug - (10/31/06)
     
  472. ROCHE PROGRESSES ITS ORAL POLYMERASE INHIBITOR INTO PHASE II DEVELOPMENT STUDY IN PATIENTS WITH HEPATITIS C - (10/31/06)
     
  473. Novel Robust Hepatitis C Virus Mouse Efficacy Model - (10/31/06)
     
  474. AVI BioPharma technology ineffective against hepatitis C - (10/31/06)
     
  475. AASLD: Roche HCV Polymerase Inhibitor Shows Potency: 4 log viral load reduction - (10/31/06)
     
  476. AASLD: Valopicitabine (NM283) plus Peg-Interferon in Treatment-Naive Hepatitis C Patients with HCV Genotype-1 Infection: HCV RNA Clearance During 24 Weeks of Treatment - (10/31/06)
     
  477. AASLD: SELECTION AND CHARACTERIZATION OF HEPATITIS C VIRUS REPLICONS RESISTANT TO A POTENT POLYMERASE INHIBITOR A-837093 - (10/30/06)
     
  478. AASLD: In vitro antiviral effects of combinations of Abbott HCV polymerase inhibitors with IFN or NS3/4A protease inhibitors - (10/30/06)
     
  479. AASLD: The Antiviral Efficacy of an HCV Polymerase inhibitor in the Chimpanzee Model: Genotypic and Phenotypic Analysis - (10/30/06)
     
  480. AASLD: Coffee Appears to Reduce Risk of Fibrosis in HCV+ - (10/30/06)
     
  481. AASLD: Daily Cannabis Use by HCV+ Increased Odds of Moderate to Severe Fibrosis by 7- Fold - (10/30/06)
     
  482. AASLD: Higher Fixed Dosing with PEGASYS in Difficult-to-Treat Patients - (10/30/06)
     
  483. AASLD: Early Week 4 Response Predicts SVR in Genotype 1 - (10/30/06)
     
  484. AASLD: Roche's Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients - (10/30/06)
     
  485. AASLD: Update on NM283, HCV Polymerase Inhibitor, at New 200 mg Dose - (10/30/06)
     
  486. AASLD: New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting - (10/30/06)
     
  487. AASLD: Valeant Pharmaceuticals Previews 24-Week Results of Direct Trial for Infergen (Consensus Interferon) - (10/30/06)
     
  488. ICAAC: Baseline viral load (400,000 IU/mL) as a predictor of SVR rate with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in HCV/HIV Coinfected in Apricot Study - (10/16/06)
     
  489. ICAAC: HIV Antiretroviral-Related Hyperlipidemia is Mitigated by HCV Co-Infection - (10/16/06)
     
  490. HUMAN GENOME SCIENCES ANNOUNCES PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR ALBUFERON IN CHRONIC HEPATITIS C - (10/05/06)
     
  491. ICAAC: Roche HCV Polymerase Inhibitor: two preclinical studies - (10/02/06)
     
  492. ICAAC: HCV-796 Displays Potent Antiviral Activity in Replicon and in Chimeric Mice Infected with Hepatitis C Virus (HCV) - (10/02/06)
     
  493. ICAAC: The Nucleoside Inhibitor MK-0608 Mediates Suppression of HCV Replication for >30 Days in Chronically Infected Chimpanzees - (10/02/06)
     
  494. Insulin resistance and HCV: Will new knowledge modify clinical management? - (09/21/06)
     
  495. GAY MEN AND HEP C - (09/21/06)
     
  496. 28 Days of the Hepatitis C Protease Inhibitor VX-950, in Combination With PEG-Interferon-ALFA-2a and Ribavirin, Is Well-Tolerated and Demonstrates Robust Antiviral Effects - (09/18/06)
     
  497. Viramidine Did Not Meet Efficacy Endpoint in Viser2 - (09/15/06)
     
  498. Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions - (09/15/06)
     
  499. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C - (09/15/06)
     
  500. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-α2b plus ribavirin treatment in a patient with hepatitis B and C coinfection - (09/15/06)
     
  501. New Compound Protects Against Liver Cancer - (09/11/06)
     
  502. Hepatitis C virus therapies - (09/08/06)
     
  503. Prevention of mortality from hepatitis B and hepatitis C - (09/08/06)
     
  504. Treating viral hepatitis C: efficacy, side effects, and complications - (09/07/06)
     
  505. FDA Hepatitis C Public Hearing on Study Design Issues for New Hep C Drugs - (09/07/06)
     
  506. NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon - (08/31/06)
     
  507. ViroPharma Announces Positive Data From Phase 1b Combination Study Of HCV-796 And Pegylated Interferon In Hepatitis C Patients - (08/31/06)
     
  508. Hispanics Have More Aggressive Liver Disease in LA County Hepatitis Clinic - (08/31/06)
     
  509. IAC: HCV Death Rate Doubles Among IDUs in Last 5 Years - (08/24/06)
     
  510. Peregrine's Final HCV Phase 1a Study Results Accepted for Oral Presentation at AASLD Annual Meeting - (08/16/06)
     
  511. Cost effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C - (08/14/06)
     
  512. 72 Weeks Pegasys/RBV Improves SVR for When HCV-RNA is Detectable at Week 4 - (08/09/06)
     
  513. Pegasys/RBV in African-Americans - (08/09/06)
     
  514. Pre-treatment LDL & T-Cholesterol Predict SVR in HCV+ - (08/08/06)
     
  515. Acute hepatitis C: Hi Dosage and compliance Predict SVR - (08/08/06)
     
  516. Interferon Enhancer Drug EMZ702 Study + PegIFN/RBV - (08/04/06)
     
  517. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial - (08/01/06)
     
  518. A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content - (08/01/06)
     
  519. CDC Study on HCV Risk Transmission & Tattoos/Body Piercing, Snorting Drugs - (08/01/06)
     
  520. Canada To Compensate HCV-Infected Tainted Blood Victims - (07/31/06)
     
  521. Unique HIV Clinic in India - (07/31/06)
     
  522. BMI, Waist Size, and Fitness & Central Adiposity Associated with NAFLD (nonalcoholic fatty liver disease) - (07/30/06)
     
  523. GlaxoSmithKline announces FDA approval and the launch of Avandamet (rosiglitazone maleate and metformin HCl) as inital therapy in the treatment of type 2 diabetes - (07/30/06)
     
  524. Cancer Incidence Much Higher in People with Hep B or C - (07/24/06)
     
  525. What Is the Role of GB Virus C Infection in Hepatitis C Virus/HIV Coinfection? - (07/20/06)
     
  526. Statin Drugs Inhibit HCV in vitro - (07/10/06)
     
  527. Diagnostic and Prognostic Role of α-Fetoprotein in Hepatocellular Carcinoma: Both or Neither? - (07/10/06)
     
  528. Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences - (07/06/06)
     
  529. Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C - (06/30/06)
     
  530. Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV - (06/30/06)
     
  531. Phase 2 Study of VX-950, Pegasys, and Copegus in Hepatitis C- study sites - (06/30/06)
     
  532. Hepatic Steatosis Is Associated with Fibrosis, Nucleoside Analogue Use, and Hepatitis C Virus Genotype 3 Infection in HIV-Seropositive Patients: Steatosis was present in 69% of patients - (06/29/06)
     
  533. Dideoxynucleoside Analogues Should Be Used Cautiously in Patients with Hepatic Steatosis EDITORIAL - (06/29/06)
     
  534. Anadys/Novartis HCV Toll-Receptor Drug Study Stopped for Animal Toxicity - (06/26/06)
     
  535. A very low toxic agent induces apoptosis and reduces growth of human hepatocellular carcinoma cells - (06/23/06)
     
  536. BREASTFEEDING & HCV TRANSMISSION - (06/23/06)
     
  537. Drug Resistance Wksp: New HCV Polymerase Inhibitor is in Early Development; resistance at 282 is associated with polymerase drug resistance, but PSI-6130 may remain active when mutation is present - (06/20/06)
     
  538. Drug Resistance Wksp: New achievements in hepatitis C virus research and their implications for antiviral therapy - (06/20/06)
     
  539. Drug Resistance Wksp: Coffee, Cirrhosis, and Transaminase Enzymes - (06/14/06)
     
  540. Drug Resistance Wksp: Selection and characterization of mutations conferring resistance to a HCV RNA dependent RNA polymerase inhibitor A-848837 in vitro - (06/14/06)
     
  541. Drug Resistance Wksp: Merck's New HCV Polymerase Inhibitor Drug Reduces HCV Viral Load by 5.7 Log in 7 Days in Chimps - (06/14/06)
     
  542. Coffee Consumption May Protect Liver from Alcohol - (06/13/06)
     
  543. BMI, Insulin Resistance Contribute to Fibrosis - (06/12/06)
     
  544. Thiazolidinediones and hepatic fibrosis: don't wait too long - (06/12/06)
     
  545. DDW: Consensus IFN vs Pegasys for 72 Wks in Peg/RBV Relapsers - (06/12/06)
     
  546. DDW: Consensus IFN for Peg/RBV Nonresponders in Germany - (06/12/06)
     
  547. DDW: Hi-Dose Consensus IFN in Prior Peg/RBV Users - (06/12/06)
     
  548. DDW: Consensus Interferon in Peg/RBV Relapsers & Nonresponders in Dallas: 48 weeks end of treatment viral response - (06/12/06)
     
  549. HCV is Detected in Liver of HCV Antibody-Positive But HCV RNA Negative Patients, so don't assume HCV has been cleared if viral load is undetectable - (06/08/06)
     
  550. Sexual Dysfunction is Highly Prevalent Among Men with Chronic Hepatitis C Virus Infection and Negatively Impacts Health-Related Quality of Life - (06/07/06)
     
  551. Study Finds Diabetes is Associated with HCV & HBV, Triglycerides, Steatosis & More Severe Fibrosis - (06/07/06)
     
  552. Novartis strengthens infectious disease portfolio by acquiring rights to Albuferon(TM), a hepatitis C interferon drug set to enter Phase III trials - (06/06/06)
     
  553. Peginterferon alfa-2a (Pegasys) and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response - (06/06/06)
     
  554. Study finds steatosis (fatty liver) is more common & severe in HIV coinfected compared to HCV monoinfected - (06/06/06)
     
  555. DDW: The Impact of Growth Factors on Pegylated Interferon alfa-2b and Ribavirin Dose Reduction in Patients Treated for Genotype 1 Chronic Hepatitis C - (06/06/06)
     
  556. DDW: Preclinical Characteristics of ITMN-191, an Orally Active Inhibitor of the HCV NS3/4A Protease Nominated for Preclinical Development - (06/06/06)
     
  557. DDW: Pharmacokinetic Analysis and Liver Concentrations of a Series of Macrocyclic Peptidomimetic Inhibitors of HCV NS3/4A Protease: Identification of ITMN-191, a Potent NS3/4A Protease Inhibitor with High Liver Exposure Across Multiple Species - (06/06/06)
     
  558. DDW: Growth Factors Versus Dose Reduction for Pegylated Interferon alfa-2b and Ribavirin-Associated Neutropenia and Anemia in HIV/HCV Co-Infected Patients - (06/06/06)
     
  559. DDW: Smoking Cigarettes Reduced SVR Rates in Peg/RBV Study - (06/05/06)
     
  560. DDW: The Effect of Liver Fibrosis and Cirrhosis on SVR in 4913 Patients With Hepatitis C: Results From The WIN-R Trial - (06/05/06)
     
  561. DDW: Affect of Viral Load on SVR Rates to PegIntron/RBV in Genotype 1 Patients in WIN-R Study - (06/05/06)
     
  562. DDW: Differences In Treatment Outcome To Antiviral Therapy Based On Genotype And Viral Load In Hepatitis C Genotypes 2 And 3 In The WIN-R Trial - (06/02/06)
     
  563. Metabolics/Belly Fat Advance HCV Disease - (05/30/06)
     
  564. EASL: A Phase 2 Dose-Escalation Study of (Albuferon) albumin interferon alfa-2b Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic Hepatitis C Infection Phase - (05/30/06)
     
  565. EASL: Interim (Week 12) Phase 2B Virological Efficacy and Safety Results of Albuferon (albumin interferon alfa-2b) Combined with Ribavirin in Genotype 1 Treatment-naive Chronic Hepatitis C Infection - (05/30/06)
     
  566. DDW: NM283 + Peg: differences in response between treatment naives & nonresponders; dose reductions for safety concerns - (05/26/06)
     
  567. DDW: HCV-796, new HCV non-nucleoside- 14 day study - (05/26/06)
     
  568. DDW: "Week 12 Antiviral Activity of Higher Doses of albumin interferon alfa-2b (Albuferon) Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic HCV-Infection" - (05/25/06)
     
  569. DDW: Entecavir (ETV) Demonstrates Consistent Responses Throughout Baseline Disease and Demographic Subgroups for the Treatment of Lamivudine-Refractory (LVD-ref) HBeAg(+) Patients with Chronic Hepatitis B - (05/25/06)
     
  570. DDW: Final Analysis of Virological Outcomes and Resistance During 5 Years of adefovir Dipivoxil Monotherapy in HBeAg-Negative Patients - (05/25/06)
     
  571. DDW: 96-Week Viral Suppression Data From Two Studies Presented For BARACLUDE (entecavir) In Chronically-Infected Hepatitis B Patients - (05/24/06)
     
  572. DDW: Results from a Cost-Effectiveness Study Demonstrate Positive Economic Impact with PEGASYS Treatment - (05/24/06)
     
  573. DDW: G-CSF is safe and improves adherence and SVR in HCV patients with genotype 1 who develop Peg-IFNa-2b related severe neutropenia - (05/24/06)
     
  574. DDW: African-Americans' response to Interferon: preliminary results from Virahep C Study - (05/24/06)
     
  575. DDW: VX-950 HCV Protease Inhibitor + Pegasys/RBV: 28 days study results in treatment-naive - (05/24/06)
     
  576. Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients - (05/23/06)
     
  577. DDW: ViroPharma Announces Presentation of HCV-796 Phase 1b Data at Digestive Disease Week - (05/23/06)
     
  578. DDW: HCV Protease ITMN 191, In Vitro Resistance - - (05/23/06)
     
  579. DDW: High Dose Albuferon -early data - (05/23/06)
     
  580. DDW: Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity - (05/23/06)
     
  581. DDW: Reliable early prediction of viral relapse by detection of minimal residual hepatitis C viremia at treatment week 12 with Sensitive HCV Viral load Test - (05/22/06)
     
  582. DDW: High Prevalence of Hepatitis C Virus Infection Among Russian Immigrants in the New York City Metropolitan Area: Results of A Community-Based Screening Program - (05/22/06)
     
  583. DDW: Noninvasive Biomarker Test for Fatty Liver - (05/22/06)
     
  584. DDW: Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients - (05/22/06)
     
  585. DDW: The prevalence of metabolic syndrome (53%) in veterans with chronic hepatitis C virus - (05/22/06)
     
  586. Study details hepatitis C ability to block immune system response - (05/19/06)
     
  587. Elevated ALT Associated with Heart Disease - (05/19/06)